Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest Update

Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) was the target of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 11,400 shares, an increase of 2,750.0% from the March 31st total of 400 shares. Based on an average trading volume of 206,900 shares, the short-interest ratio is currently 0.1 days.

Oncotelic Therapeutics Price Performance

Shares of OTLC remained flat at $0.04 during trading on Thursday. 10,259 shares of the company’s stock were exchanged, compared to its average volume of 71,367. Oncotelic Therapeutics has a 1-year low of $0.01 and a 1-year high of $0.05. The business’s fifty day moving average is $0.04 and its 200-day moving average is $0.04. The company has a debt-to-equity ratio of 0.16, a current ratio of 0.02 and a quick ratio of 0.02.

Oncotelic Therapeutics Company Profile

Oncotelic Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.